BR112022023897A2 - Um composto de azelastina para uso como substância antiviral, uso de um composto de azelastina como desinfetante - Google Patents
Um composto de azelastina para uso como substância antiviral, uso de um composto de azelastina como desinfetanteInfo
- Publication number
- BR112022023897A2 BR112022023897A2 BR112022023897A BR112022023897A BR112022023897A2 BR 112022023897 A2 BR112022023897 A2 BR 112022023897A2 BR 112022023897 A BR112022023897 A BR 112022023897A BR 112022023897 A BR112022023897 A BR 112022023897A BR 112022023897 A2 BR112022023897 A2 BR 112022023897A2
- Authority
- BR
- Brazil
- Prior art keywords
- azelastine compound
- azelastine
- compound
- disinfectant
- antiviral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
UM COMPOSTO DE AZELASTINA PARA USO COMO SUBSTÂNCIA ANTIVIRAL, USO DE UM COMPOSTO DE AZELASTINA COMO DESINFETANTE. A invenção se refere a um composto de Azelastina numa quantidade antiviral eficaz para uso como substância antiviral numa preparação farmacêutica para uso em tratamento profilático ou terapêutico de um indivíduo que necessita de tratamento antiviral.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20177451 | 2020-05-29 | ||
EP20184767.0A EP3936132A1 (en) | 2020-07-08 | 2020-07-08 | Azelastine as antiviral treatment |
EP20195740 | 2020-09-11 | ||
EP21171333 | 2021-04-29 | ||
PCT/EP2021/064338 WO2021239943A1 (en) | 2020-05-29 | 2021-05-28 | Azelastine as antiviral treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022023897A2 true BR112022023897A2 (pt) | 2023-04-04 |
Family
ID=76059910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022023897A BR112022023897A2 (pt) | 2020-05-29 | 2021-05-28 | Um composto de azelastina para uso como substância antiviral, uso de um composto de azelastina como desinfetante |
Country Status (19)
Country | Link |
---|---|
US (3) | US20230201216A1 (pt) |
EP (2) | EP3934653B1 (pt) |
JP (1) | JP2023529025A (pt) |
KR (1) | KR20230021009A (pt) |
CN (1) | CN116406273A (pt) |
AU (1) | AU2021279280A1 (pt) |
BR (1) | BR112022023897A2 (pt) |
CA (1) | CA3184167A1 (pt) |
DK (1) | DK3934653T3 (pt) |
ES (1) | ES2937145T3 (pt) |
FI (1) | FI3934653T3 (pt) |
HU (1) | HUE060929T2 (pt) |
IL (1) | IL298543A (pt) |
LT (1) | LT3934653T (pt) |
MX (1) | MX2022015074A (pt) |
PL (1) | PL3934653T3 (pt) |
RS (1) | RS63940B1 (pt) |
SI (1) | SI3934653T1 (pt) |
WO (1) | WO2021239943A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100311656A1 (en) * | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
US8758816B2 (en) * | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
JP2008285474A (ja) * | 2007-04-17 | 2008-11-27 | Daiichi Sankyo Healthcare Co Ltd | 抗アデノウイルス剤を含有する医薬組成物 |
US8642069B2 (en) * | 2008-08-27 | 2014-02-04 | Alexander D. Goldin | Composition and method for treating colds |
US20230129326A1 (en) * | 2020-04-07 | 2023-04-27 | University Of Florida Research Foundation, Incorporated | Methods to prevent sars-cov-2 infection and treat covid-19 |
WO2021207729A1 (en) * | 2020-04-10 | 2021-10-14 | Mubarak Kamal Khan | Compositions and methods for modulating ace2 receptor |
CN113521289A (zh) * | 2020-04-16 | 2021-10-22 | 中国科学院上海药物研究所 | 15种药物有效成分在抗病毒感染中的应用 |
-
2021
- 2021-05-28 CN CN202180059038.4A patent/CN116406273A/zh active Pending
- 2021-05-28 FI FIEP21727186.5T patent/FI3934653T3/fi active
- 2021-05-28 JP JP2023516644A patent/JP2023529025A/ja active Pending
- 2021-05-28 LT LTEPPCT/EP2021/064338T patent/LT3934653T/lt unknown
- 2021-05-28 ES ES21727186T patent/ES2937145T3/es active Active
- 2021-05-28 CA CA3184167A patent/CA3184167A1/en active Pending
- 2021-05-28 SI SI202130029T patent/SI3934653T1/sl unknown
- 2021-05-28 BR BR112022023897A patent/BR112022023897A2/pt unknown
- 2021-05-28 HU HUE21727186A patent/HUE060929T2/hu unknown
- 2021-05-28 DK DK21727186.5T patent/DK3934653T3/da active
- 2021-05-28 EP EP21727186.5A patent/EP3934653B1/en active Active
- 2021-05-28 PL PL21727186.5T patent/PL3934653T3/pl unknown
- 2021-05-28 IL IL298543A patent/IL298543A/en unknown
- 2021-05-28 EP EP22206040.2A patent/EP4190333A1/en active Pending
- 2021-05-28 US US17/928,422 patent/US20230201216A1/en active Pending
- 2021-05-28 RS RS20230083A patent/RS63940B1/sr unknown
- 2021-05-28 US US17/333,857 patent/US11273163B2/en active Active
- 2021-05-28 KR KR1020227045014A patent/KR20230021009A/ko unknown
- 2021-05-28 WO PCT/EP2021/064338 patent/WO2021239943A1/en active Application Filing
- 2021-05-28 MX MX2022015074A patent/MX2022015074A/es unknown
- 2021-05-28 AU AU2021279280A patent/AU2021279280A1/en active Pending
- 2021-12-27 US US17/562,973 patent/US11433080B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HUE060929T2 (hu) | 2023-04-28 |
CN116406273A (zh) | 2023-07-07 |
SI3934653T1 (sl) | 2023-04-28 |
LT3934653T (lt) | 2023-02-27 |
IL298543A (en) | 2023-01-01 |
JP2023529025A (ja) | 2023-07-06 |
EP3934653B1 (en) | 2022-11-09 |
ES2937145T3 (es) | 2023-03-24 |
EP3934653A1 (en) | 2022-01-12 |
US11273163B2 (en) | 2022-03-15 |
US11433080B2 (en) | 2022-09-06 |
KR20230021009A (ko) | 2023-02-13 |
WO2021239943A1 (en) | 2021-12-02 |
US20210369730A1 (en) | 2021-12-02 |
MX2022015074A (es) | 2023-02-16 |
AU2021279280A1 (en) | 2023-01-05 |
DK3934653T3 (da) | 2023-02-13 |
PL3934653T3 (pl) | 2023-03-13 |
US20220143040A1 (en) | 2022-05-12 |
RS63940B1 (sr) | 2023-02-28 |
US20230201216A1 (en) | 2023-06-29 |
FI3934653T3 (fi) | 2023-03-01 |
CA3184167A1 (en) | 2021-12-02 |
EP4190333A1 (en) | 2023-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
CL2015001864A1 (es) | Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih. | |
UY37168A (es) | Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
PA8780201A1 (es) | Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
CL2008000862A1 (es) | Compuestos derivados de triazolonas, inhibidores no nucleosidos de transcriptasa inversa; composicion farmaceutica que contiene a dichos compuestos; y uso del compuesto para tratar la infeccion del vih-1. | |
UY32919A (es) | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos | |
BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
CR20140144A (es) | Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
BR112015019412A2 (pt) | inibidores de bace1 | |
CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
AR104068A1 (es) | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
GT201700220A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
BR112015026259A2 (pt) | combinações de ligantes de adrenoceptor alfa-2 e receptor sigma | |
CO2021012579A2 (es) | Compuestos útiles en la terapia del vih | |
BR112018014540A2 (pt) | formulações/composições compreendendo inibidor de btk | |
BR112021025732A2 (pt) | Inibidores macrocíclicos de mcl-1 | |
BR112022023897A2 (pt) | Um composto de azelastina para uso como substância antiviral, uso de um composto de azelastina como desinfetante | |
CO2021001925A2 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação |